Biocon Pharma Receives US FDA Dapagliflozin Approval

Biocon Pharma Limited receives US FDA approval for Dapagliflozin Tablets 5mg and 10mg for type 2 diabetes treatment.
Approval strengthens Biocon's diabetes portfolio including oral formulations, biosimilar insulin and GLP-1 peptides.
Product will be manufactured at Biocon's FDA-approved facilities meeting global quality standards.